Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
45,497
archived clinical trials in
Breast Cancer

DS-8201a in Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Breast Cancer [DESTINY-Breast01]
A Phase 2, Multicenter, Open-Label Study of DS-8201a, an Anti-HER2-Antibody Drug Conjugate (ADC) for HER2-Positive, Unresectable and/or Metastatic Breast Cancer Subjects Previously Treated With T-DM1
Status: Enrolling
Updated:  12/31/1969
North Shore Hematology Oncology Associates PC DBA NY Cancer and Blood Specialists
mi
from
East Setauket, NY
DS-8201a in Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Breast Cancer [DESTINY-Breast01]
A Phase 2, Multicenter, Open-Label Study of DS-8201a, an Anti-HER2-Antibody Drug Conjugate (ADC) for HER2-Positive, Unresectable and/or Metastatic Breast Cancer Subjects Previously Treated With T-DM1
Status: Enrolling
Updated: 12/31/1969
North Shore Hematology Oncology Associates PC DBA NY Cancer and Blood Specialists
mi
from
East Setauket, NY
Click here to add this to my saved trials
DS-8201a in Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Breast Cancer [DESTINY-Breast01]
A Phase 2, Multicenter, Open-Label Study of DS-8201a, an Anti-HER2-Antibody Drug Conjugate (ADC) for HER2-Positive, Unresectable and/or Metastatic Breast Cancer Subjects Previously Treated With T-DM1
Status: Enrolling
Updated:  12/31/1969
Memorial Sloan Kettering Cancer Center
mi
from
New York, NY
DS-8201a in Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Breast Cancer [DESTINY-Breast01]
A Phase 2, Multicenter, Open-Label Study of DS-8201a, an Anti-HER2-Antibody Drug Conjugate (ADC) for HER2-Positive, Unresectable and/or Metastatic Breast Cancer Subjects Previously Treated With T-DM1
Status: Enrolling
Updated: 12/31/1969
Memorial Sloan Kettering Cancer Center
mi
from
New York, NY
Click here to add this to my saved trials
DS-8201a in Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Breast Cancer [DESTINY-Breast01]
A Phase 2, Multicenter, Open-Label Study of DS-8201a, an Anti-HER2-Antibody Drug Conjugate (ADC) for HER2-Positive, Unresectable and/or Metastatic Breast Cancer Subjects Previously Treated With T-DM1
Status: Enrolling
Updated:  12/31/1969
University of Cincinnati Medical Center
mi
from
Cincinnati, OH
DS-8201a in Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Breast Cancer [DESTINY-Breast01]
A Phase 2, Multicenter, Open-Label Study of DS-8201a, an Anti-HER2-Antibody Drug Conjugate (ADC) for HER2-Positive, Unresectable and/or Metastatic Breast Cancer Subjects Previously Treated With T-DM1
Status: Enrolling
Updated: 12/31/1969
University of Cincinnati Medical Center
mi
from
Cincinnati, OH
Click here to add this to my saved trials
DS-8201a in Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Breast Cancer [DESTINY-Breast01]
A Phase 2, Multicenter, Open-Label Study of DS-8201a, an Anti-HER2-Antibody Drug Conjugate (ADC) for HER2-Positive, Unresectable and/or Metastatic Breast Cancer Subjects Previously Treated With T-DM1
Status: Enrolling
Updated:  12/31/1969
Specialist Global Research
mi
from
Hialeah, FL
DS-8201a in Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Breast Cancer [DESTINY-Breast01]
A Phase 2, Multicenter, Open-Label Study of DS-8201a, an Anti-HER2-Antibody Drug Conjugate (ADC) for HER2-Positive, Unresectable and/or Metastatic Breast Cancer Subjects Previously Treated With T-DM1
Status: Enrolling
Updated: 12/31/1969
Specialist Global Research
mi
from
Hialeah, FL
Click here to add this to my saved trials
DS-8201a in Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Breast Cancer [DESTINY-Breast01]
A Phase 2, Multicenter, Open-Label Study of DS-8201a, an Anti-HER2-Antibody Drug Conjugate (ADC) for HER2-Positive, Unresectable and/or Metastatic Breast Cancer Subjects Previously Treated With T-DM1
Status: Enrolling
Updated:  12/31/1969
Allegheny General Hospital
mi
from
Pittsburgh, PA
DS-8201a in Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Breast Cancer [DESTINY-Breast01]
A Phase 2, Multicenter, Open-Label Study of DS-8201a, an Anti-HER2-Antibody Drug Conjugate (ADC) for HER2-Positive, Unresectable and/or Metastatic Breast Cancer Subjects Previously Treated With T-DM1
Status: Enrolling
Updated: 12/31/1969
Allegheny General Hospital
mi
from
Pittsburgh, PA
Click here to add this to my saved trials
DS-8201a in Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Breast Cancer [DESTINY-Breast01]
A Phase 2, Multicenter, Open-Label Study of DS-8201a, an Anti-HER2-Antibody Drug Conjugate (ADC) for HER2-Positive, Unresectable and/or Metastatic Breast Cancer Subjects Previously Treated With T-DM1
Status: Enrolling
Updated:  12/31/1969
Arizona Oncology Associates
mi
from
Tucson, AZ
DS-8201a in Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Breast Cancer [DESTINY-Breast01]
A Phase 2, Multicenter, Open-Label Study of DS-8201a, an Anti-HER2-Antibody Drug Conjugate (ADC) for HER2-Positive, Unresectable and/or Metastatic Breast Cancer Subjects Previously Treated With T-DM1
Status: Enrolling
Updated: 12/31/1969
Arizona Oncology Associates
mi
from
Tucson, AZ
Click here to add this to my saved trials
DS-8201a in Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Breast Cancer [DESTINY-Breast01]
A Phase 2, Multicenter, Open-Label Study of DS-8201a, an Anti-HER2-Antibody Drug Conjugate (ADC) for HER2-Positive, Unresectable and/or Metastatic Breast Cancer Subjects Previously Treated With T-DM1
Status: Enrolling
Updated:  12/31/1969
Sansum Clinic
mi
from
Santa Barbara, CA
DS-8201a in Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Breast Cancer [DESTINY-Breast01]
A Phase 2, Multicenter, Open-Label Study of DS-8201a, an Anti-HER2-Antibody Drug Conjugate (ADC) for HER2-Positive, Unresectable and/or Metastatic Breast Cancer Subjects Previously Treated With T-DM1
Status: Enrolling
Updated: 12/31/1969
Sansum Clinic
mi
from
Santa Barbara, CA
Click here to add this to my saved trials
DS-8201a in Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Breast Cancer [DESTINY-Breast01]
A Phase 2, Multicenter, Open-Label Study of DS-8201a, an Anti-HER2-Antibody Drug Conjugate (ADC) for HER2-Positive, Unresectable and/or Metastatic Breast Cancer Subjects Previously Treated With T-DM1
Status: Enrolling
Updated:  12/31/1969
Aultman Hospital Cancer Center
mi
from
Canton, OH
DS-8201a in Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Breast Cancer [DESTINY-Breast01]
A Phase 2, Multicenter, Open-Label Study of DS-8201a, an Anti-HER2-Antibody Drug Conjugate (ADC) for HER2-Positive, Unresectable and/or Metastatic Breast Cancer Subjects Previously Treated With T-DM1
Status: Enrolling
Updated: 12/31/1969
Aultman Hospital Cancer Center
mi
from
Canton, OH
Click here to add this to my saved trials
DS-8201a in Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Breast Cancer [DESTINY-Breast01]
A Phase 2, Multicenter, Open-Label Study of DS-8201a, an Anti-HER2-Antibody Drug Conjugate (ADC) for HER2-Positive, Unresectable and/or Metastatic Breast Cancer Subjects Previously Treated With T-DM1
Status: Enrolling
Updated:  12/31/1969
Texas Oncology, PA
mi
from
Dallas, TX
DS-8201a in Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Breast Cancer [DESTINY-Breast01]
A Phase 2, Multicenter, Open-Label Study of DS-8201a, an Anti-HER2-Antibody Drug Conjugate (ADC) for HER2-Positive, Unresectable and/or Metastatic Breast Cancer Subjects Previously Treated With T-DM1
Status: Enrolling
Updated: 12/31/1969
Texas Oncology, PA
mi
from
Dallas, TX
Click here to add this to my saved trials
DS-8201a in Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Breast Cancer [DESTINY-Breast01]
A Phase 2, Multicenter, Open-Label Study of DS-8201a, an Anti-HER2-Antibody Drug Conjugate (ADC) for HER2-Positive, Unresectable and/or Metastatic Breast Cancer Subjects Previously Treated With T-DM1
Status: Enrolling
Updated:  12/31/1969
Texas Oncology - Memorial City
mi
from
Houston, TX
DS-8201a in Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Breast Cancer [DESTINY-Breast01]
A Phase 2, Multicenter, Open-Label Study of DS-8201a, an Anti-HER2-Antibody Drug Conjugate (ADC) for HER2-Positive, Unresectable and/or Metastatic Breast Cancer Subjects Previously Treated With T-DM1
Status: Enrolling
Updated: 12/31/1969
Texas Oncology - Memorial City
mi
from
Houston, TX
Click here to add this to my saved trials
DS-8201a in Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Breast Cancer [DESTINY-Breast01]
A Phase 2, Multicenter, Open-Label Study of DS-8201a, an Anti-HER2-Antibody Drug Conjugate (ADC) for HER2-Positive, Unresectable and/or Metastatic Breast Cancer Subjects Previously Treated With T-DM1
Status: Enrolling
Updated:  12/31/1969
Texas Oncology, P.A. - Longview
mi
from
Tyler, TX
DS-8201a in Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Breast Cancer [DESTINY-Breast01]
A Phase 2, Multicenter, Open-Label Study of DS-8201a, an Anti-HER2-Antibody Drug Conjugate (ADC) for HER2-Positive, Unresectable and/or Metastatic Breast Cancer Subjects Previously Treated With T-DM1
Status: Enrolling
Updated: 12/31/1969
Texas Oncology, P.A. - Longview
mi
from
Tyler, TX
Click here to add this to my saved trials
DS-8201a in Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Breast Cancer [DESTINY-Breast01]
A Phase 2, Multicenter, Open-Label Study of DS-8201a, an Anti-HER2-Antibody Drug Conjugate (ADC) for HER2-Positive, Unresectable and/or Metastatic Breast Cancer Subjects Previously Treated With T-DM1
Status: Enrolling
Updated:  12/31/1969
The Regents of the University of California
mi
from
Los Angeles, CA
DS-8201a in Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Breast Cancer [DESTINY-Breast01]
A Phase 2, Multicenter, Open-Label Study of DS-8201a, an Anti-HER2-Antibody Drug Conjugate (ADC) for HER2-Positive, Unresectable and/or Metastatic Breast Cancer Subjects Previously Treated With T-DM1
Status: Enrolling
Updated: 12/31/1969
The Regents of the University of California
mi
from
Los Angeles, CA
Click here to add this to my saved trials
DS-8201a in Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Breast Cancer [DESTINY-Breast01]
A Phase 2, Multicenter, Open-Label Study of DS-8201a, an Anti-HER2-Antibody Drug Conjugate (ADC) for HER2-Positive, Unresectable and/or Metastatic Breast Cancer Subjects Previously Treated With T-DM1
Status: Enrolling
Updated:  12/31/1969
Sylvester Comprehensive Cancer Center - Deerfield Beach
mi
from
Boca Raton, FL
DS-8201a in Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Breast Cancer [DESTINY-Breast01]
A Phase 2, Multicenter, Open-Label Study of DS-8201a, an Anti-HER2-Antibody Drug Conjugate (ADC) for HER2-Positive, Unresectable and/or Metastatic Breast Cancer Subjects Previously Treated With T-DM1
Status: Enrolling
Updated: 12/31/1969
Sylvester Comprehensive Cancer Center - Deerfield Beach
mi
from
Boca Raton, FL
Click here to add this to my saved trials
DS-8201a in Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Breast Cancer [DESTINY-Breast01]
A Phase 2, Multicenter, Open-Label Study of DS-8201a, an Anti-HER2-Antibody Drug Conjugate (ADC) for HER2-Positive, Unresectable and/or Metastatic Breast Cancer Subjects Previously Treated With T-DM1
Status: Enrolling
Updated:  12/31/1969
Piedmont Cancer Institute, P.C.
mi
from
Atlanta, GA
DS-8201a in Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Breast Cancer [DESTINY-Breast01]
A Phase 2, Multicenter, Open-Label Study of DS-8201a, an Anti-HER2-Antibody Drug Conjugate (ADC) for HER2-Positive, Unresectable and/or Metastatic Breast Cancer Subjects Previously Treated With T-DM1
Status: Enrolling
Updated: 12/31/1969
Piedmont Cancer Institute, P.C.
mi
from
Atlanta, GA
Click here to add this to my saved trials
DS-8201a in Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Breast Cancer [DESTINY-Breast01]
A Phase 2, Multicenter, Open-Label Study of DS-8201a, an Anti-HER2-Antibody Drug Conjugate (ADC) for HER2-Positive, Unresectable and/or Metastatic Breast Cancer Subjects Previously Treated With T-DM1
Status: Enrolling
Updated:  12/31/1969
Univ of Hawaii
mi
from
Honolulu, HI
DS-8201a in Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Breast Cancer [DESTINY-Breast01]
A Phase 2, Multicenter, Open-Label Study of DS-8201a, an Anti-HER2-Antibody Drug Conjugate (ADC) for HER2-Positive, Unresectable and/or Metastatic Breast Cancer Subjects Previously Treated With T-DM1
Status: Enrolling
Updated: 12/31/1969
Univ of Hawaii
mi
from
Honolulu, HI
Click here to add this to my saved trials
DS-8201a in Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Breast Cancer [DESTINY-Breast01]
A Phase 2, Multicenter, Open-Label Study of DS-8201a, an Anti-HER2-Antibody Drug Conjugate (ADC) for HER2-Positive, Unresectable and/or Metastatic Breast Cancer Subjects Previously Treated With T-DM1
Status: Enrolling
Updated:  12/31/1969
Norton Healthcare
mi
from
Louisville, KY
DS-8201a in Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Breast Cancer [DESTINY-Breast01]
A Phase 2, Multicenter, Open-Label Study of DS-8201a, an Anti-HER2-Antibody Drug Conjugate (ADC) for HER2-Positive, Unresectable and/or Metastatic Breast Cancer Subjects Previously Treated With T-DM1
Status: Enrolling
Updated: 12/31/1969
Norton Healthcare
mi
from
Louisville, KY
Click here to add this to my saved trials
DS-8201a in Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Breast Cancer [DESTINY-Breast01]
A Phase 2, Multicenter, Open-Label Study of DS-8201a, an Anti-HER2-Antibody Drug Conjugate (ADC) for HER2-Positive, Unresectable and/or Metastatic Breast Cancer Subjects Previously Treated With T-DM1
Status: Enrolling
Updated:  12/31/1969
Beth Israel Deaconess Medical Center
mi
from
Boston, MA
DS-8201a in Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Breast Cancer [DESTINY-Breast01]
A Phase 2, Multicenter, Open-Label Study of DS-8201a, an Anti-HER2-Antibody Drug Conjugate (ADC) for HER2-Positive, Unresectable and/or Metastatic Breast Cancer Subjects Previously Treated With T-DM1
Status: Enrolling
Updated: 12/31/1969
Beth Israel Deaconess Medical Center
mi
from
Boston, MA
Click here to add this to my saved trials
DS-8201a in Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Breast Cancer [DESTINY-Breast01]
A Phase 2, Multicenter, Open-Label Study of DS-8201a, an Anti-HER2-Antibody Drug Conjugate (ADC) for HER2-Positive, Unresectable and/or Metastatic Breast Cancer Subjects Previously Treated With T-DM1
Status: Enrolling
Updated:  12/31/1969
Dana-Farber Cancer Institute
mi
from
Boston, MA
DS-8201a in Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Breast Cancer [DESTINY-Breast01]
A Phase 2, Multicenter, Open-Label Study of DS-8201a, an Anti-HER2-Antibody Drug Conjugate (ADC) for HER2-Positive, Unresectable and/or Metastatic Breast Cancer Subjects Previously Treated With T-DM1
Status: Enrolling
Updated: 12/31/1969
Dana-Farber Cancer Institute
mi
from
Boston, MA
Click here to add this to my saved trials
DS-8201a in Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Breast Cancer [DESTINY-Breast01]
A Phase 2, Multicenter, Open-Label Study of DS-8201a, an Anti-HER2-Antibody Drug Conjugate (ADC) for HER2-Positive, Unresectable and/or Metastatic Breast Cancer Subjects Previously Treated With T-DM1
Status: Enrolling
Updated:  12/31/1969
Henry Ford Hospital
mi
from
Detroit, MI
DS-8201a in Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Breast Cancer [DESTINY-Breast01]
A Phase 2, Multicenter, Open-Label Study of DS-8201a, an Anti-HER2-Antibody Drug Conjugate (ADC) for HER2-Positive, Unresectable and/or Metastatic Breast Cancer Subjects Previously Treated With T-DM1
Status: Enrolling
Updated: 12/31/1969
Henry Ford Hospital
mi
from
Detroit, MI
Click here to add this to my saved trials
DS-8201a in Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Breast Cancer [DESTINY-Breast01]
A Phase 2, Multicenter, Open-Label Study of DS-8201a, an Anti-HER2-Antibody Drug Conjugate (ADC) for HER2-Positive, Unresectable and/or Metastatic Breast Cancer Subjects Previously Treated With T-DM1
Status: Enrolling
Updated:  12/31/1969
UPMC Cancer Center
mi
from
Pittsburgh, PA
DS-8201a in Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Breast Cancer [DESTINY-Breast01]
A Phase 2, Multicenter, Open-Label Study of DS-8201a, an Anti-HER2-Antibody Drug Conjugate (ADC) for HER2-Positive, Unresectable and/or Metastatic Breast Cancer Subjects Previously Treated With T-DM1
Status: Enrolling
Updated: 12/31/1969
UPMC Cancer Center
mi
from
Pittsburgh, PA
Click here to add this to my saved trials
DS-8201a in Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Breast Cancer [DESTINY-Breast01]
A Phase 2, Multicenter, Open-Label Study of DS-8201a, an Anti-HER2-Antibody Drug Conjugate (ADC) for HER2-Positive, Unresectable and/or Metastatic Breast Cancer Subjects Previously Treated With T-DM1
Status: Enrolling
Updated:  12/31/1969
St. Francis Hospital
mi
from
Greenville, SC
DS-8201a in Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Breast Cancer [DESTINY-Breast01]
A Phase 2, Multicenter, Open-Label Study of DS-8201a, an Anti-HER2-Antibody Drug Conjugate (ADC) for HER2-Positive, Unresectable and/or Metastatic Breast Cancer Subjects Previously Treated With T-DM1
Status: Enrolling
Updated: 12/31/1969
St. Francis Hospital
mi
from
Greenville, SC
Click here to add this to my saved trials
DS-8201a in Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Breast Cancer [DESTINY-Breast01]
A Phase 2, Multicenter, Open-Label Study of DS-8201a, an Anti-HER2-Antibody Drug Conjugate (ADC) for HER2-Positive, Unresectable and/or Metastatic Breast Cancer Subjects Previously Treated With T-DM1
Status: Enrolling
Updated:  12/31/1969
M.D. Anderson Cancer Center
mi
from
Houston, TX
DS-8201a in Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Breast Cancer [DESTINY-Breast01]
A Phase 2, Multicenter, Open-Label Study of DS-8201a, an Anti-HER2-Antibody Drug Conjugate (ADC) for HER2-Positive, Unresectable and/or Metastatic Breast Cancer Subjects Previously Treated With T-DM1
Status: Enrolling
Updated: 12/31/1969
M.D. Anderson Cancer Center
mi
from
Houston, TX
Click here to add this to my saved trials
DS-8201a in Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Breast Cancer [DESTINY-Breast01]
A Phase 2, Multicenter, Open-Label Study of DS-8201a, an Anti-HER2-Antibody Drug Conjugate (ADC) for HER2-Positive, Unresectable and/or Metastatic Breast Cancer Subjects Previously Treated With T-DM1
Status: Enrolling
Updated:  12/31/1969
University of Texas Health Science Center at Tyler
mi
from
Tyler, TX
DS-8201a in Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Breast Cancer [DESTINY-Breast01]
A Phase 2, Multicenter, Open-Label Study of DS-8201a, an Anti-HER2-Antibody Drug Conjugate (ADC) for HER2-Positive, Unresectable and/or Metastatic Breast Cancer Subjects Previously Treated With T-DM1
Status: Enrolling
Updated: 12/31/1969
University of Texas Health Science Center at Tyler
mi
from
Tyler, TX
Click here to add this to my saved trials
DS-8201a in Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Breast Cancer [DESTINY-Breast01]
A Phase 2, Multicenter, Open-Label Study of DS-8201a, an Anti-HER2-Antibody Drug Conjugate (ADC) for HER2-Positive, Unresectable and/or Metastatic Breast Cancer Subjects Previously Treated With T-DM1
Status: Enrolling
Updated:  12/31/1969
Virginia Cancer Specialists, PC
mi
from
Fairfax, VA
DS-8201a in Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Breast Cancer [DESTINY-Breast01]
A Phase 2, Multicenter, Open-Label Study of DS-8201a, an Anti-HER2-Antibody Drug Conjugate (ADC) for HER2-Positive, Unresectable and/or Metastatic Breast Cancer Subjects Previously Treated With T-DM1
Status: Enrolling
Updated: 12/31/1969
Virginia Cancer Specialists, PC
mi
from
Fairfax, VA
Click here to add this to my saved trials
DS-8201a in Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Breast Cancer [DESTINY-Breast01]
A Phase 2, Multicenter, Open-Label Study of DS-8201a, an Anti-HER2-Antibody Drug Conjugate (ADC) for HER2-Positive, Unresectable and/or Metastatic Breast Cancer Subjects Previously Treated With T-DM1
Status: Enrolling
Updated:  12/31/1969
Imeldaziekenhuis
mi
from
Bonheiden,
DS-8201a in Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Breast Cancer [DESTINY-Breast01]
A Phase 2, Multicenter, Open-Label Study of DS-8201a, an Anti-HER2-Antibody Drug Conjugate (ADC) for HER2-Positive, Unresectable and/or Metastatic Breast Cancer Subjects Previously Treated With T-DM1
Status: Enrolling
Updated: 12/31/1969
Imeldaziekenhuis
mi
from
Bonheiden,
Click here to add this to my saved trials
DS-8201a in Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Breast Cancer [DESTINY-Breast01]
A Phase 2, Multicenter, Open-Label Study of DS-8201a, an Anti-HER2-Antibody Drug Conjugate (ADC) for HER2-Positive, Unresectable and/or Metastatic Breast Cancer Subjects Previously Treated With T-DM1
Status: Enrolling
Updated:  12/31/1969
Ochsner Clinic Foundation
mi
from
New Orleans, LA
DS-8201a in Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Breast Cancer [DESTINY-Breast01]
A Phase 2, Multicenter, Open-Label Study of DS-8201a, an Anti-HER2-Antibody Drug Conjugate (ADC) for HER2-Positive, Unresectable and/or Metastatic Breast Cancer Subjects Previously Treated With T-DM1
Status: Enrolling
Updated: 12/31/1969
Ochsner Clinic Foundation
mi
from
New Orleans, LA
Click here to add this to my saved trials
DS-8201a in Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Breast Cancer [DESTINY-Breast01]
A Phase 2, Multicenter, Open-Label Study of DS-8201a, an Anti-HER2-Antibody Drug Conjugate (ADC) for HER2-Positive, Unresectable and/or Metastatic Breast Cancer Subjects Previously Treated With T-DM1
Status: Enrolling
Updated:  12/31/1969
Accurate Clinical Research, Inc.
mi
from
Baytown, TX
DS-8201a in Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Breast Cancer [DESTINY-Breast01]
A Phase 2, Multicenter, Open-Label Study of DS-8201a, an Anti-HER2-Antibody Drug Conjugate (ADC) for HER2-Positive, Unresectable and/or Metastatic Breast Cancer Subjects Previously Treated With T-DM1
Status: Enrolling
Updated: 12/31/1969
Accurate Clinical Research, Inc.
mi
from
Baytown, TX
Click here to add this to my saved trials
DS-8201a in Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Breast Cancer [DESTINY-Breast01]
A Phase 2, Multicenter, Open-Label Study of DS-8201a, an Anti-HER2-Antibody Drug Conjugate (ADC) for HER2-Positive, Unresectable and/or Metastatic Breast Cancer Subjects Previously Treated With T-DM1
Status: Enrolling
Updated:  12/31/1969
Providence Regional Medical Center Everett
mi
from
Everett, WA
DS-8201a in Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Breast Cancer [DESTINY-Breast01]
A Phase 2, Multicenter, Open-Label Study of DS-8201a, an Anti-HER2-Antibody Drug Conjugate (ADC) for HER2-Positive, Unresectable and/or Metastatic Breast Cancer Subjects Previously Treated With T-DM1
Status: Enrolling
Updated: 12/31/1969
Providence Regional Medical Center Everett
mi
from
Everett, WA
Click here to add this to my saved trials
DS-8201a in Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Breast Cancer [DESTINY-Breast01]
A Phase 2, Multicenter, Open-Label Study of DS-8201a, an Anti-HER2-Antibody Drug Conjugate (ADC) for HER2-Positive, Unresectable and/or Metastatic Breast Cancer Subjects Previously Treated With T-DM1
Status: Enrolling
Updated:  12/31/1969
University of California at San Francisco
mi
from
San Francisco, CA
DS-8201a in Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Breast Cancer [DESTINY-Breast01]
A Phase 2, Multicenter, Open-Label Study of DS-8201a, an Anti-HER2-Antibody Drug Conjugate (ADC) for HER2-Positive, Unresectable and/or Metastatic Breast Cancer Subjects Previously Treated With T-DM1
Status: Enrolling
Updated: 12/31/1969
University of California at San Francisco
mi
from
San Francisco, CA
Click here to add this to my saved trials
DS-8201a in Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Breast Cancer [DESTINY-Breast01]
A Phase 2, Multicenter, Open-Label Study of DS-8201a, an Anti-HER2-Antibody Drug Conjugate (ADC) for HER2-Positive, Unresectable and/or Metastatic Breast Cancer Subjects Previously Treated With T-DM1
Status: Enrolling
Updated:  12/31/1969
Straub Medical Center
mi
from
Honolulu, HI
DS-8201a in Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Breast Cancer [DESTINY-Breast01]
A Phase 2, Multicenter, Open-Label Study of DS-8201a, an Anti-HER2-Antibody Drug Conjugate (ADC) for HER2-Positive, Unresectable and/or Metastatic Breast Cancer Subjects Previously Treated With T-DM1
Status: Enrolling
Updated: 12/31/1969
Straub Medical Center
mi
from
Honolulu, HI
Click here to add this to my saved trials
DS-8201a in Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Breast Cancer [DESTINY-Breast01]
A Phase 2, Multicenter, Open-Label Study of DS-8201a, an Anti-HER2-Antibody Drug Conjugate (ADC) for HER2-Positive, Unresectable and/or Metastatic Breast Cancer Subjects Previously Treated With T-DM1
Status: Enrolling
Updated:  12/31/1969
University of Louisville Research Foundation, Inc.
mi
from
Louisville, KY
DS-8201a in Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Breast Cancer [DESTINY-Breast01]
A Phase 2, Multicenter, Open-Label Study of DS-8201a, an Anti-HER2-Antibody Drug Conjugate (ADC) for HER2-Positive, Unresectable and/or Metastatic Breast Cancer Subjects Previously Treated With T-DM1
Status: Enrolling
Updated: 12/31/1969
University of Louisville Research Foundation, Inc.
mi
from
Louisville, KY
Click here to add this to my saved trials
DS-8201a in Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Breast Cancer [DESTINY-Breast01]
A Phase 2, Multicenter, Open-Label Study of DS-8201a, an Anti-HER2-Antibody Drug Conjugate (ADC) for HER2-Positive, Unresectable and/or Metastatic Breast Cancer Subjects Previously Treated With T-DM1
Status: Enrolling
Updated:  12/31/1969
The Methodist Hospital Research Institute
mi
from
Houston, TX
DS-8201a in Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Breast Cancer [DESTINY-Breast01]
A Phase 2, Multicenter, Open-Label Study of DS-8201a, an Anti-HER2-Antibody Drug Conjugate (ADC) for HER2-Positive, Unresectable and/or Metastatic Breast Cancer Subjects Previously Treated With T-DM1
Status: Enrolling
Updated: 12/31/1969
The Methodist Hospital Research Institute
mi
from
Houston, TX
Click here to add this to my saved trials
Survivorship Care Plans in a Community Oncology Practice
Feasibility of Delivering Electronic Health Record (EHR)-Based Survivorship Care Plans and Planning to Cancer Survivors in a Community Oncology Practice
Status: Enrolling
Updated:  12/31/1969
UW Cancer Center at ProHealth Care
mi
from
Waukesha, WI
Survivorship Care Plans in a Community Oncology Practice
Feasibility of Delivering Electronic Health Record (EHR)-Based Survivorship Care Plans and Planning to Cancer Survivors in a Community Oncology Practice
Status: Enrolling
Updated: 12/31/1969
UW Cancer Center at ProHealth Care
mi
from
Waukesha, WI
Click here to add this to my saved trials
Radiofrequency Identification Technology in Locating Non-palpable Breast Lesions in Patients Undergoing Surgery
Pilot Trial Evaluating a Miniature Radiofrequency Tag for Localization of Non-palpable Breast Lesions for Surgery
Status: Enrolling
Updated:  12/31/1969
UCLA Jonsson Comprehensive Cancer Center
mi
from
Los Angeles, CA
Radiofrequency Identification Technology in Locating Non-palpable Breast Lesions in Patients Undergoing Surgery
Pilot Trial Evaluating a Miniature Radiofrequency Tag for Localization of Non-palpable Breast Lesions for Surgery
Status: Enrolling
Updated: 12/31/1969
UCLA Jonsson Comprehensive Cancer Center
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Simulated-altitude to Optimize Aerobic Exercise Among Breast Cancer Survivors With Limited Mobility
Simulated-Altitude as an Adjunct to Optimize Aerobic Exercise in Obese Breast Cancer Survivors With Limited Ambulatory Function: Pilot Randomized Trial
Status: Enrolling
Updated:  12/31/1969
University of Alabama at Birmingham
mi
from
Birmingham, AL
Simulated-altitude to Optimize Aerobic Exercise Among Breast Cancer Survivors With Limited Mobility
Simulated-Altitude as an Adjunct to Optimize Aerobic Exercise in Obese Breast Cancer Survivors With Limited Ambulatory Function: Pilot Randomized Trial
Status: Enrolling
Updated: 12/31/1969
University of Alabama at Birmingham
mi
from
Birmingham, AL
Click here to add this to my saved trials
Predictors of Adjuvant Endocrine Therapy in Women With Breast Cancer
Predictors of Adjuvant Endocrine Therapy in Women With Breast Cancer
Status: Enrolling
Updated:  12/31/1969
Georgetown University
mi
from
Washington,
Predictors of Adjuvant Endocrine Therapy in Women With Breast Cancer
Predictors of Adjuvant Endocrine Therapy in Women With Breast Cancer
Status: Enrolling
Updated: 12/31/1969
Georgetown University
mi
from
Washington,
Click here to add this to my saved trials
Mindful Movement in Women Receiving Adjuvant or Neoadjuvant Therapy for Breast Cancer
The Role of Mindful Movement in Women Receiving Adjuvant or Neoadjuvant Therapy for Breast Cancer
Status: Enrolling
Updated:  12/31/1969
Washington University School of Medicine
mi
from
Saint Louis, MO
Mindful Movement in Women Receiving Adjuvant or Neoadjuvant Therapy for Breast Cancer
The Role of Mindful Movement in Women Receiving Adjuvant or Neoadjuvant Therapy for Breast Cancer
Status: Enrolling
Updated: 12/31/1969
Washington University School of Medicine
mi
from
Saint Louis, MO
Click here to add this to my saved trials
A Study to Evaluate the Safety, Pharmacokinetics and Clinical Activity of RO6870810 and Atezolizumab (PD-L1 Antibody) in Participants With Advanced Ovarian Cancer or Triple Negative Breast Cancer
Open Label, Dose Finding and Expansion Phase IB Study to Evaluate the Safety, Pharmacokinetics and Clinical Activity of RO6870810 and Atezolizumab (Pd L1 Antibody) in Pateints With Advanced Ovarian Cancer or Triple Negative Breast Cancer
Status: Enrolling
Updated:  12/31/1969
Dana-Farber Cancer Institute
mi
from
Boston, MA
A Study to Evaluate the Safety, Pharmacokinetics and Clinical Activity of RO6870810 and Atezolizumab (PD-L1 Antibody) in Participants With Advanced Ovarian Cancer or Triple Negative Breast Cancer
Open Label, Dose Finding and Expansion Phase IB Study to Evaluate the Safety, Pharmacokinetics and Clinical Activity of RO6870810 and Atezolizumab (Pd L1 Antibody) in Pateints With Advanced Ovarian Cancer or Triple Negative Breast Cancer
Status: Enrolling
Updated: 12/31/1969
Dana-Farber Cancer Institute
mi
from
Boston, MA
Click here to add this to my saved trials
A Study to Evaluate the Safety, Pharmacokinetics and Clinical Activity of RO6870810 and Atezolizumab (PD-L1 Antibody) in Participants With Advanced Ovarian Cancer or Triple Negative Breast Cancer
Open Label, Dose Finding and Expansion Phase IB Study to Evaluate the Safety, Pharmacokinetics and Clinical Activity of RO6870810 and Atezolizumab (Pd L1 Antibody) in Pateints With Advanced Ovarian Cancer or Triple Negative Breast Cancer
Status: Enrolling
Updated:  12/31/1969
Sarah Cannon Res Inst; TN Onc
mi
from
Nashville, TN
A Study to Evaluate the Safety, Pharmacokinetics and Clinical Activity of RO6870810 and Atezolizumab (PD-L1 Antibody) in Participants With Advanced Ovarian Cancer or Triple Negative Breast Cancer
Open Label, Dose Finding and Expansion Phase IB Study to Evaluate the Safety, Pharmacokinetics and Clinical Activity of RO6870810 and Atezolizumab (Pd L1 Antibody) in Pateints With Advanced Ovarian Cancer or Triple Negative Breast Cancer
Status: Enrolling
Updated: 12/31/1969
Sarah Cannon Res Inst; TN Onc
mi
from
Nashville, TN
Click here to add this to my saved trials
A Study to Evaluate the Safety, Pharmacokinetics and Clinical Activity of RO6870810 and Atezolizumab (PD-L1 Antibody) in Participants With Advanced Ovarian Cancer or Triple Negative Breast Cancer
Open Label, Dose Finding and Expansion Phase IB Study to Evaluate the Safety, Pharmacokinetics and Clinical Activity of RO6870810 and Atezolizumab (Pd L1 Antibody) in Pateints With Advanced Ovarian Cancer or Triple Negative Breast Cancer
Status: Enrolling
Updated:  12/31/1969
St. Vincents Hospital Sydney
mi
from
Darlinghurst,
A Study to Evaluate the Safety, Pharmacokinetics and Clinical Activity of RO6870810 and Atezolizumab (PD-L1 Antibody) in Participants With Advanced Ovarian Cancer or Triple Negative Breast Cancer
Open Label, Dose Finding and Expansion Phase IB Study to Evaluate the Safety, Pharmacokinetics and Clinical Activity of RO6870810 and Atezolizumab (Pd L1 Antibody) in Pateints With Advanced Ovarian Cancer or Triple Negative Breast Cancer
Status: Enrolling
Updated: 12/31/1969
St. Vincents Hospital Sydney
mi
from
Darlinghurst,
Click here to add this to my saved trials
A Study to Evaluate the Safety, Pharmacokinetics and Clinical Activity of RO6870810 and Atezolizumab (PD-L1 Antibody) in Participants With Advanced Ovarian Cancer or Triple Negative Breast Cancer
Open Label, Dose Finding and Expansion Phase IB Study to Evaluate the Safety, Pharmacokinetics and Clinical Activity of RO6870810 and Atezolizumab (Pd L1 Antibody) in Pateints With Advanced Ovarian Cancer or Triple Negative Breast Cancer
Status: Enrolling
Updated:  12/31/1969
The University of California, San Diego
mi
from
La Jolla, CA
A Study to Evaluate the Safety, Pharmacokinetics and Clinical Activity of RO6870810 and Atezolizumab (PD-L1 Antibody) in Participants With Advanced Ovarian Cancer or Triple Negative Breast Cancer
Open Label, Dose Finding and Expansion Phase IB Study to Evaluate the Safety, Pharmacokinetics and Clinical Activity of RO6870810 and Atezolizumab (Pd L1 Antibody) in Pateints With Advanced Ovarian Cancer or Triple Negative Breast Cancer
Status: Enrolling
Updated: 12/31/1969
The University of California, San Diego
mi
from
La Jolla, CA
Click here to add this to my saved trials
A Study to Evaluate the Safety, Pharmacokinetics and Clinical Activity of RO6870810 and Atezolizumab (PD-L1 Antibody) in Participants With Advanced Ovarian Cancer or Triple Negative Breast Cancer
Open Label, Dose Finding and Expansion Phase IB Study to Evaluate the Safety, Pharmacokinetics and Clinical Activity of RO6870810 and Atezolizumab (Pd L1 Antibody) in Pateints With Advanced Ovarian Cancer or Triple Negative Breast Cancer
Status: Enrolling
Updated:  12/31/1969
UCLA Cancer Center
mi
from
Santa Monica, CA
A Study to Evaluate the Safety, Pharmacokinetics and Clinical Activity of RO6870810 and Atezolizumab (PD-L1 Antibody) in Participants With Advanced Ovarian Cancer or Triple Negative Breast Cancer
Open Label, Dose Finding and Expansion Phase IB Study to Evaluate the Safety, Pharmacokinetics and Clinical Activity of RO6870810 and Atezolizumab (Pd L1 Antibody) in Pateints With Advanced Ovarian Cancer or Triple Negative Breast Cancer
Status: Enrolling
Updated: 12/31/1969
UCLA Cancer Center
mi
from
Santa Monica, CA
Click here to add this to my saved trials
A Study to Evaluate the Safety, Pharmacokinetics and Clinical Activity of RO6870810 and Atezolizumab (PD-L1 Antibody) in Participants With Advanced Ovarian Cancer or Triple Negative Breast Cancer
Open Label, Dose Finding and Expansion Phase IB Study to Evaluate the Safety, Pharmacokinetics and Clinical Activity of RO6870810 and Atezolizumab (Pd L1 Antibody) in Pateints With Advanced Ovarian Cancer or Triple Negative Breast Cancer
Status: Enrolling
Updated:  12/31/1969
Oklahoma University Health Sciences Center
mi
from
Oklahoma City, OK
A Study to Evaluate the Safety, Pharmacokinetics and Clinical Activity of RO6870810 and Atezolizumab (PD-L1 Antibody) in Participants With Advanced Ovarian Cancer or Triple Negative Breast Cancer
Open Label, Dose Finding and Expansion Phase IB Study to Evaluate the Safety, Pharmacokinetics and Clinical Activity of RO6870810 and Atezolizumab (Pd L1 Antibody) in Pateints With Advanced Ovarian Cancer or Triple Negative Breast Cancer
Status: Enrolling
Updated: 12/31/1969
Oklahoma University Health Sciences Center
mi
from
Oklahoma City, OK
Click here to add this to my saved trials
A Study to Evaluate the Safety, Pharmacokinetics and Clinical Activity of RO6870810 and Atezolizumab (PD-L1 Antibody) in Participants With Advanced Ovarian Cancer or Triple Negative Breast Cancer
Open Label, Dose Finding and Expansion Phase IB Study to Evaluate the Safety, Pharmacokinetics and Clinical Activity of RO6870810 and Atezolizumab (Pd L1 Antibody) in Pateints With Advanced Ovarian Cancer or Triple Negative Breast Cancer
Status: Enrolling
Updated:  12/31/1969
University of Pennsylvania Health System; Cancer Center
mi
from
Philadelphia, PA
A Study to Evaluate the Safety, Pharmacokinetics and Clinical Activity of RO6870810 and Atezolizumab (PD-L1 Antibody) in Participants With Advanced Ovarian Cancer or Triple Negative Breast Cancer
Open Label, Dose Finding and Expansion Phase IB Study to Evaluate the Safety, Pharmacokinetics and Clinical Activity of RO6870810 and Atezolizumab (Pd L1 Antibody) in Pateints With Advanced Ovarian Cancer or Triple Negative Breast Cancer
Status: Enrolling
Updated: 12/31/1969
University of Pennsylvania Health System; Cancer Center
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Endocrine Therapy With or Without Abemaciclib (LY2835219) Following Surgery in Participants With Breast Cancer
A Randomized, Open-Label, Phase 3 Study of Abemaciclib Combined With Standard Adjuvant Endocrine Therapy Versus Standard Adjuvant Endocrine Therapy Alone in Patients With High Risk, Node Positive, Early Stage, Hormone Receptor Positive, Human Epidermal Receptor 2 Negative, Breast Cancer
Status: Enrolling
Updated:  12/31/1969
Highlands Oncology Group, P.A.
mi
from
Fayetteville, AR
Endocrine Therapy With or Without Abemaciclib (LY2835219) Following Surgery in Participants With Breast Cancer
A Randomized, Open-Label, Phase 3 Study of Abemaciclib Combined With Standard Adjuvant Endocrine Therapy Versus Standard Adjuvant Endocrine Therapy Alone in Patients With High Risk, Node Positive, Early Stage, Hormone Receptor Positive, Human Epidermal Receptor 2 Negative, Breast Cancer
Status: Enrolling
Updated: 12/31/1969
Highlands Oncology Group, P.A.
mi
from
Fayetteville, AR
Click here to add this to my saved trials
Endocrine Therapy With or Without Abemaciclib (LY2835219) Following Surgery in Participants With Breast Cancer
A Randomized, Open-Label, Phase 3 Study of Abemaciclib Combined With Standard Adjuvant Endocrine Therapy Versus Standard Adjuvant Endocrine Therapy Alone in Patients With High Risk, Node Positive, Early Stage, Hormone Receptor Positive, Human Epidermal Receptor 2 Negative, Breast Cancer
Status: Enrolling
Updated:  12/31/1969
St. Bernard's Medical Center
mi
from
Jonesboro, AR
Endocrine Therapy With or Without Abemaciclib (LY2835219) Following Surgery in Participants With Breast Cancer
A Randomized, Open-Label, Phase 3 Study of Abemaciclib Combined With Standard Adjuvant Endocrine Therapy Versus Standard Adjuvant Endocrine Therapy Alone in Patients With High Risk, Node Positive, Early Stage, Hormone Receptor Positive, Human Epidermal Receptor 2 Negative, Breast Cancer
Status: Enrolling
Updated: 12/31/1969
St. Bernard's Medical Center
mi
from
Jonesboro, AR
Click here to add this to my saved trials
Endocrine Therapy With or Without Abemaciclib (LY2835219) Following Surgery in Participants With Breast Cancer
A Randomized, Open-Label, Phase 3 Study of Abemaciclib Combined With Standard Adjuvant Endocrine Therapy Versus Standard Adjuvant Endocrine Therapy Alone in Patients With High Risk, Node Positive, Early Stage, Hormone Receptor Positive, Human Epidermal Receptor 2 Negative, Breast Cancer
Status: Enrolling
Updated:  12/31/1969
Beverly Hills Cancer Center
mi
from
Beverly Hills, CA
Endocrine Therapy With or Without Abemaciclib (LY2835219) Following Surgery in Participants With Breast Cancer
A Randomized, Open-Label, Phase 3 Study of Abemaciclib Combined With Standard Adjuvant Endocrine Therapy Versus Standard Adjuvant Endocrine Therapy Alone in Patients With High Risk, Node Positive, Early Stage, Hormone Receptor Positive, Human Epidermal Receptor 2 Negative, Breast Cancer
Status: Enrolling
Updated: 12/31/1969
Beverly Hills Cancer Center
mi
from
Beverly Hills, CA
Click here to add this to my saved trials
Endocrine Therapy With or Without Abemaciclib (LY2835219) Following Surgery in Participants With Breast Cancer
A Randomized, Open-Label, Phase 3 Study of Abemaciclib Combined With Standard Adjuvant Endocrine Therapy Versus Standard Adjuvant Endocrine Therapy Alone in Patients With High Risk, Node Positive, Early Stage, Hormone Receptor Positive, Human Epidermal Receptor 2 Negative, Breast Cancer
Status: Enrolling
Updated:  12/31/1969
California Cancer Associates for Research and Excellence (CCARE)
mi
from
Fresno, CA
Endocrine Therapy With or Without Abemaciclib (LY2835219) Following Surgery in Participants With Breast Cancer
A Randomized, Open-Label, Phase 3 Study of Abemaciclib Combined With Standard Adjuvant Endocrine Therapy Versus Standard Adjuvant Endocrine Therapy Alone in Patients With High Risk, Node Positive, Early Stage, Hormone Receptor Positive, Human Epidermal Receptor 2 Negative, Breast Cancer
Status: Enrolling
Updated: 12/31/1969
California Cancer Associates for Research and Excellence (CCARE)
mi
from
Fresno, CA
Click here to add this to my saved trials
Endocrine Therapy With or Without Abemaciclib (LY2835219) Following Surgery in Participants With Breast Cancer
A Randomized, Open-Label, Phase 3 Study of Abemaciclib Combined With Standard Adjuvant Endocrine Therapy Versus Standard Adjuvant Endocrine Therapy Alone in Patients With High Risk, Node Positive, Early Stage, Hormone Receptor Positive, Human Epidermal Receptor 2 Negative, Breast Cancer
Status: Enrolling
Updated:  12/31/1969
Cancer Center of Santa Barbara with SANSUM Clinic
mi
from
Santa Barbara, CA
Endocrine Therapy With or Without Abemaciclib (LY2835219) Following Surgery in Participants With Breast Cancer
A Randomized, Open-Label, Phase 3 Study of Abemaciclib Combined With Standard Adjuvant Endocrine Therapy Versus Standard Adjuvant Endocrine Therapy Alone in Patients With High Risk, Node Positive, Early Stage, Hormone Receptor Positive, Human Epidermal Receptor 2 Negative, Breast Cancer
Status: Enrolling
Updated: 12/31/1969
Cancer Center of Santa Barbara with SANSUM Clinic
mi
from
Santa Barbara, CA
Click here to add this to my saved trials
Endocrine Therapy With or Without Abemaciclib (LY2835219) Following Surgery in Participants With Breast Cancer
A Randomized, Open-Label, Phase 3 Study of Abemaciclib Combined With Standard Adjuvant Endocrine Therapy Versus Standard Adjuvant Endocrine Therapy Alone in Patients With High Risk, Node Positive, Early Stage, Hormone Receptor Positive, Human Epidermal Receptor 2 Negative, Breast Cancer
Status: Enrolling
Updated:  12/31/1969
Florida Cancer Specialists
mi
from
Fort Myers, FL
Endocrine Therapy With or Without Abemaciclib (LY2835219) Following Surgery in Participants With Breast Cancer
A Randomized, Open-Label, Phase 3 Study of Abemaciclib Combined With Standard Adjuvant Endocrine Therapy Versus Standard Adjuvant Endocrine Therapy Alone in Patients With High Risk, Node Positive, Early Stage, Hormone Receptor Positive, Human Epidermal Receptor 2 Negative, Breast Cancer
Status: Enrolling
Updated: 12/31/1969
Florida Cancer Specialists
mi
from
Fort Myers, FL
Click here to add this to my saved trials